Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction
Stephen J. Greene(Duke University), Gregg C. Fonarow, Adrian F. Hernandez(Duke University), John A. Spertus(Spertus Institute for Jewish Learning and Leadership), Javed Butler(University of Mississippi Medical Center), Laine Thomas(Clinical Research Institute), Muthiah Vaduganathan(Harvard University), Fredonia B. Williams(Heartsong), Nancy M. Albert(Cleveland Clinic), Adam D. DeVore(Duke University), Carol I. Duffy(Novartis (United States)), J. Herbert Patterson(University of North Carolina at Chapel Hill), Anne S. Hellkamp(Clinical Research Institute)
Cited by 153
Related Papers
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k